Divis Laboratories Q1 Results FY27: Uniresearch Predictions, Analyst Views and Key Watchpoints

June 25, 2026
Posted by: Ankit Jaiswal
Category: News

Divis Laboratories Q1 Results FY27: Uniresearch projects Revenue Rs 2,800 Cr | PAT Rs 643 Cr (30-analyst consensus). Q4 FY26: Rev Rs 2,831 Cr | PAT Rs 751 Cr.

The Divis Laboratories Q1 Results FY27 outlook is anchored on Q4 FY26 verified actuals and Uniresearch analysis applying the 30-analyst FY27 consensus to Q1 FY26 verified actuals. Uniresearch projects Revenue Rs 2,800 Cr (+16.2% YoY) and PAT Rs 643 Cr (+18.0% YoY). Prepared by Ankit Jaiswal.

Click Here – Get Free Investment Predictions

Table of Contents

Divis Laboratories – Uniresearch Prediction

Metric	Q1 FY26 Actual	Q1 Results FY27 Uniresearch Prediction	YoY Change	Source
Divis Laboratories Revenue (Rs Cr)	2,410	2,800	+16.2%	Uniresearch \| 30-analyst consensus applied to Q1 FY26 verified actual
PAT (Rs Cr)	545	643	+18.0%	Uniresearch \| 30-analyst consensus applied to Q1 FY26 verified actual
Avg Analyst Target	Rs 7,066	12-month view	–	Analyst consensus (30 analysts)

Predictions apply 30-analyst FY27 consensus (Rev +16.2%, PAT +18.0%) to Q1 FY26 verified actuals. Not guaranteed outcomes.

Divis Laboratories Q4 FY26 Key Metrics – Baseline for Divis Laboratories

Metric	Q4 FY26 Actual	YoY Change	Source
Revenue (Rs Cr)	2,831	+9.5% YoY	Consolidated quarterly financial data
PAT (Rs Cr)	751	+13.4% YoY	Consolidated quarterly financial data

What Analysts Are Saying About Divis Laboratories

Across 30 analysts covering Divis Laboratories, the FY27 consensus projects revenue growth of +16.2% and profit growth of +18.0%, with an average 12-month price target of Rs 7,066. The Q1 Results FY27 prediction of Rs 643 Cr PAT and Rs 2,800 Cr Revenue reflects this consensus applied to verified Q1 FY26 actuals.

Key Watchpoints for Divis Laboratories

Revenue Delivery vs Consensus in Divis Laboratories Q1 Results FY27

The primary watchpoint is whether Q1 Results FY27 Revenue delivers in line with Uniresearch projection of Rs 2,800 Cr (based on the 30-analyst consensus growth of +16.2%). Q1 FY26 base was Rs 2,410 Cr.

PAT Performance in Divis Laboratories Q1 Results FY27

The Q1 Results FY27 PAT watchpoint is whether Divis Laboratories achieves Rs 643 Cr as projected (consensus PAT growth: +18.0% from Q1 FY26 base of Rs 545 Cr). Q4 FY26 PAT was Rs 751 Cr.

Risks to the Divis Laboratories Prediction

Below-Consensus Revenue Growth in Divis Laboratories Q1 Results FY27

If Q1 Results FY27 revenue comes in below the +16.2% consensus, actual revenue would fall short of Rs 2,800 Cr. Sector-specific demand conditions are the primary variable.

PAT Pressure in Divis Laboratories Q1 Results FY27

The PAT prediction of Rs 643 Cr could be impacted by cost escalation or one-time charges not factored into the 30-analyst consensus of +18.0%.

Conclusion: Divis Laboratories

The Divis Laboratories Uniresearch prediction of Revenue Rs 2,800 Cr and PAT Rs 643 Cr is derived from the 30-analyst consensus FY27 growth rates applied to verified Q1 FY26 actuals. No assumptions by Univest. When Q1 Results FY27 are declared, investors can benchmark actual performance against this consensus prediction. Track live updates on Univest.

Track Divis Laboratories Live on the Univest Screener

Download the Univest iOS App or Univest Android App for live Q1 Results FY27 alerts.

Disclaimer: Revenue and PAT actuals are sourced from consolidated quarterly financial data. Q1 Results FY27 Uniresearch predictions are derived by applying analyst consensus growth rates to verified Q1 FY26 actuals – these are analyst consensus projections and are not guaranteed outcomes. Investments in securities are subject to market risk. For educational purposes only. SEBI RA INH000013776.

Frequently Asked Questions on Divis Laboratories

What is Uniresearch’s PAT prediction for Divis Laboratories Q1 Results FY27?

Ans. Uniresearch projects Divis Laboratories PAT at Rs 643 Cr, applying 30-analyst FY27 profit growth consensus of +18.0% to Q1 FY26 verified PAT of Rs 545 Cr.

What is the Revenue prediction for Divis Laboratories Q1 Results FY27?

Ans. Divis Laboratories Revenue is projected at Rs 2,800 Cr by Uniresearch, applying +16.2% FY27 revenue consensus to verified Q1 FY26 base.

What were Divis Laboratories Q1 Results FY27?

Ans. Q4 FY26 consolidated Revenue was Rs 2,831 Cr (+9.5% YoY) and PAT was Rs 751 Cr (+13.4% YoY) per consolidated financial data.

Does the Divis Laboratories Q1 Results FY27 article contain Univest estimates?

Ans. No. All Divis Laboratories predictions are derived from the 30-analyst consensus applied to verified Q1 FY26 actuals.

What is the analyst target price in the Divis Laboratories Q1 Results FY27 article?

Ans. The 30-analyst consensus gives an average 12-month price target of Rs 7,066 for Divis Laboratories per the Q1 Results FY27 prediction basis.

What are the risks to the Divis Laboratories Q1 Results FY27 prediction?

Ans. Risks include below-consensus revenue growth (target: +16.2%) and PAT pressure from unexpected costs impacting the +18.0% PAT consensus.

What is the Q1 FY26 base for the Divis Laboratories Q1 Results FY27 prediction?

Ans. Q1 FY26 consolidated Revenue was Rs 2,410 Cr and PAT was Rs 545 Cr. These verified actuals form the base for the Divis Laboratories prediction.

News

Author: Ankit Jaiswal

Ankit Jaiswal is the Senior Research Analyst at Univest, leading the platform's in-house equity research desk and serving as the editorial reviewer for all research and blog content published at univest.in. With 11+ years of experience in Indian equity markets, he oversees stock recommendations, earnings analysis, sector coverage, and ensures every published article meets SEBI Research Analyst Regulations. He holds a Bachelor of Commerce (B.Com) from St. Xavier's College, Kolkata — one of India's most prestigious commerce institutions — and has cleared CMT Level 2 from the CMT Association, a globally recognised certification in technical analysis and market research. His research methodology combines fundamental analysis (earnings quality, balance sheet strength, management commentary) with advanced technical analysis (chart patterns, momentum indicators, market structure) — giving Univest's retail investors a dual-lens approach that most Indian research platforms lack. Ankit is among the most comprehensively certified analysts in Indian financial media, holding five NISM certifications: Series-XV (Research Analyst), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-VI (Depository Operations), and Series-V-A (Mutual Fund Distributors). At Univest — India's SEBI-registered research and advisory platform — Ankit's responsibilities include leading the research team, finalising stock recommendations published across Pro Lite, Pro Super, and Pro Gold advisory services, and maintaining editorial oversight of all YMYL financial content published on the blog.